低分子肝素钠治疗过敏性紫癜疗效观察

目的观察静脉用低分子肝素钠治疗过敏性紫癜的效果。方法将86例过敏性紫癜患儿随机分成两组，其中治疗组46例，对照组40例。所有患儿均接受过敏性紫癜常规治疗，治疗组在常规治疗基础上加用低分子肝素钠100-150U／（kg·d），静脉滴注，连续7d。两组患儿治疗后随访1～12个月，观察患儿症状、体征消失时间，皮疹反复发生率及紫癜性肾炎的发生率。结果治疗组症状、体征消失时间，皮疹反复发生率及紫癜性肾炎的发生率明显低于对照组，差异有统计学意义（P〈0．05）。结论低分子肝素钠可作为过敏性紫癜治疗的主要措施之一。

Effect of low molecular heparin sodium on Henoch-Schonlein purpura

Objective To investigate the curative effect of low molecular hepairn sodium on Henoch-Schonlein purpura（HSP） and the preventive effect on Henoch-Schonlem purpura nephritis. Methods Eighty-six patients with HSP were enrolled in the study and divided randomly into 2 groups： heparin group（46 cases） and control group（40 cases）. Patients in heparin group received low molecular heparin sodium by intravenous drip 100-150/（kg · d）] for 7 days on basis of the general treatment for HSP, and patients in control group received general treatment. Symptom remission time, and the incidence of recurrent skin rash were recorded. The patients were followed up for 1-12 months,and investigated the morbidity of renal injury and the time of renal injury. Results The remission times of purpura, joint pain and abdominal pain in heparin group were significantly shorter than those of control group（P〈0. 05）. The incidence of recurrent skin rash in heparin group was significantly lower than that of control group（P〈0. 05 ）. During follow-up, the morbidity of renal injury in heparin group was significantly lower than of control group（P〈0. 05）, the time of renal injury significantly delayed in heparin group compared with that of control group（P〈0. 05）. Conclusion Low molecular heparin sodium can shorten the course of HSP and prevent the developmemt of HSP nephritis.